Читать книгу Biologics, Biosimilars, and Biobetters - Группа авторов - Страница 98

 Biologics are increasingly becoming the focus of pharmaceutical research and development.

 Biologic medicines are able to treat certain diseases more efficiently than SMDs.

 The cost of biologics is resulting in significant and potentially catastrophic strain on payer systems around the globe.

 Orphan drugs will cost more than other drugs and the current development pipeline for these is relatively large.

 Computer modeling techniques will generate an even higher probability of identifying biologic drug targets in the future.